Commentary from Clinical Trials
Bremelanotide (formerly PT-141)
A market need exists for erectile dysfunction products that are differentiated by safety, efficacy and improved patient experience. A positive patient experience is critical to the success of therapies addressing this marketplace. Quality of erection, speed of onset and duration of effect differentiate Bremelanotide from the PDE-5 inhibitor class of molecules.
| "On the five point scale, I’d score the erection I had as a six.” |
| - Patient 41 |
| |
| “The extended staying power is a plus because you can go again if you want to; there’s a possibility of another encounter…” |
| - Patient 207 |
| |
| “Because the drug is an initiator, I could approach sex more confidently, knowing beforehand that it would work. I felt more at ease and relaxed…" |
| - Patient 207 |
| |
| “…PT-141 was faster than Viagra® so I prefer it…” |
| - Patient 197 |
| |
Source: Internal Market Research, October 2003
